Resources
74 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 7/26/2023 (updated 3/28/2024)
The FY22 RCORP-Implementation cohort is diverse and dynamic in every way, representing a wide variety of experience and possessing an unending amount of knowledge on SUD in rural areas. This session explored the different methods and practices this cohort uses in its efforts to address SUD prevention, treatment, and recovery. Participants had an opportunity to learn from and to build relationships with one another, which will, in turn strengthen, their RCORP projects. Additionally, they heard from RCORP program staff and the RCORP-Evaluation team about program updates and data utilization tools.
Posted 7/26/2023 (updated 3/28/2024)
This session focused on FY 21 RCORP-Implementation III. Grantees received an overview of the upcoming Sustainability Plan Year 2 deliverable, including a walkthrough of the template.
Posted 7/26/2023 (updated 3/28/2024)
During this session, the Fiscal Year 2020 (FY20) RCORP-Implementation grantees had an opportunity to share best practices, identify the impact that the RCORP grant had in their communities, learned how to use the data collected in the data dashboard, and network with other grantees. In addition, grantees received important information pertaining to evaluation, upcoming deliverables, sustainability and next steps.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.